Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $2.0 million.

  • IDEAYA Biosciences' Amortizatization of Intangibles fell 6304.31% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 3976.48%. This contributed to the annual value of $23.2 million for FY2024, which is 10109.93% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Amortizatization of Intangibles of $2.0 million as of Q3 2025, which was down 6304.31% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, IDEAYA Biosciences' Amortizatization of Intangibles peaked at $6.6 million during Q2 2024, and registered a low of -$469000.0 during Q4 2021.
  • For the 5-year period, IDEAYA Biosciences' Amortizatization of Intangibles averaged around $2.3 million, with its median value being $2.0 million (2025).
  • In the last 5 years, IDEAYA Biosciences' Amortizatization of Intangibles crashed by 898000.0% in 2021 and then soared by 96483.52% in 2023.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Amortizatization of Intangibles stood at -$469000.0 in 2021, then skyrocketed by 177.61% to $364000.0 in 2022, then skyrocketed by 964.84% to $3.9 million in 2023, then increased by 26.83% to $4.9 million in 2024, then crashed by 59.68% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles was $2.0 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.8 million in Q1 2025.